is pleased to announce the doubling of analytical capacity at its 240,000 sq. ft. North American Headquarters. The facility, built on a 40 acre site in Souderton, PA, north of Philadelphia, and occupied since 2010, delivers full-service, integrated clinical packaging, drug supply management, and technology solutions to pharmaceutical and biotech clients. The facility boasts state of the art analytical labs, supplementing existing facilities in the UK.
The analytical labs provide support for clinical packaging operations as well as stand-alone analytical services and are equipped with the latest equipment, including HPLC, UPLC, GC, UV, IR, DSC, KF and others. The additional lab investment will continue to offer these services as well as polymorph and salt screening and solid form development.
In continuing its investment, the new lab will also be equipped with the latest bathless dissolution apparatus for rapid and efficient comparative dissolution studies. This provides maximum flexibility for developing, validating and running assay, dissolution and stability methods, further complementing the large capacity stability chambers which provide all the required ICH stability conditions.
The analytical facility complements Almac’s specialty capabilities, including biocatalysis, radiolabelling, and peptide and protein synthesis. These services are all part of Almac’s comprehensive drug development services, including API and drug product development and GMP manufacture.
Almac will be exhibiting at the forthcoming Informex trade show, 14 – 17 February at Booth 2001.